The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation.

Overall, there was an increasing trend in score for the 10 mg and 25 mg psilocybin doses by day 29 compared with baseline.

also in 63,971 other papers

PANAS The placebo group showed a trend for a reduction in positive affect score from baseline to post-dose (least squares (LS) mean change = -5.0), which was not observed in either psilocybin group ( Supplementary Table S3 ).

also in 53,322 other papers